The role of benralizumab in eosinophilic immune dysfunctions: a case report-based literature review [PDF]
, 2023 In the past years, the knowledge of eosinophils playing a primary pathophysiologic role in several associated conditions has led to the development of biologics targeting therapies aiming at normalizing the immune response, reducing chronic inflammation,
Branco, Joana +5 more
core +1 more source
Precision Medicine in Targeted Therapies for Severe Asthma:Is There Any Place for "omics" Technology? [PDF]
, 2018 According to the current guidelines, severe asthma still represents a controversial topic in terms of definition and management. The introduction of novel biological therapies as a treatment option for severe asthmatic patients paved the way to a ...
Bertolini, Francesca +6 more
core +2 more sources
Effects of Therapeutic Antibodies on Gene and Protein Signatures in Asthma Patients: A Comparative Systematic Review [PDF]
, 2022 [EN]Several biologic therapies that target inflammatory modulators are now used for treating patients with uncontrolled, severe asthma. Knowledge about how this type of treatment modifies the molecular milieu is rapidly increasing.
Dávila González, Ignacio Jesús +6 more
core +1 more source
CPT: Pharmacometrics & Systems Pharmacology, 2017 Benralizumab is a humanized, afucosylated, anti‐interleukin‐5 receptor α, immunoglobulin G (IgG) 1 κ monoclonal antibody. We developed a population pharmacokinetic (PK)/pharmacodynamic (PD) model for benralizumab by analyzing PK and blood eosinophil ...
B Wang, L Yan, Z Yao, LK Roskos
doaj +1 more source
Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy [PDF]
, 2017 Reslizumab, an anti-interleukin-5 monoclonal antibody, significantly reduces exacerbation frequency and improves lung function, asthma control and quality of life in adults with severe eosinophilic asthma, as demonstrated in Phase III studies.
Brusselle, Guy +4 more
core +3 more sources
Benralizumab affects NK cell maturation and proliferation in severe asthmatic patients [PDF]
, 2023 Introduction: The mechanism of action of benralizumab is determined by its afucosylated constant fragment that binds CD16a receptors on the membrane of natural killer cells.
Bargagli, Elena +5 more
core +1 more source
Benralizumab improves patient reported outcomes and functional parameters in difficult-to-treat patients with severe asthma: Data from a real-life cohort [PDF]
, 2020 In the last decade, an increasing number of randomized controlled trials (RCTs) on biologic therapy in patients with severe asthma have included patient-reported outcomes (PROs) as secondary efficacy measures.
Albanesi, Marcello +5 more
core +1 more source
Successful treatment of eosinophilic cystitis with benralizumab
Urology Case Reports, 2020 Eosinophilic cystitis is a rare form of interstitial cystitis. It can be chronic and debilitating due to urinary frequency, dysuria, incontinence, and frequent urinary tract infections. Prior attempts at treatment have included oral and intravesical steroids, antispasmodics, and antibiotics when indicated.
W Donald Cooke, Abigail J Tarr Cooke
openaire +3 more sources
Real-life experience with benralizumab during 6 months [PDF]
BMC Pulmonary Medicine, 2020 AbstractBackgroundBenralizumab is a monoclonal antibody that binds to the human interleukin-5 (IL-5) receptor (IL-5R), thereby preventing IL-5 from binding to its receptor and inhibiting differentiation and maturation of eosinophils in the bone marrow.
A. Padilla-Galo +8 more
openaire +5 more sources
Personalized medicine with biologics for severe type 2 asthma : current status and future prospects [PDF]
, 2017 Asthma affects more than 300 million people worldwide and poses a large socioeconomic burden, particularly in the 5% to 10% of severe asthmatics. So far, each entry of new biologics in clinical trials has led to high expectations for treating all severe ...
Blanchetot, Christophe +4 more
core +3 more sources